Aeglea BioTherapeutics Doses First Patient

Aeglea BioTherapeutics Doses First Patient

We are excited to see these clinical trials available for Australian patients. These clinical trials are for a new medication for patients with classical Homocystinuria. It is an early stage study of an injection of an enzyme that would replace what is missing in Homocystinuria. If you are interested in learning more about this study, please contact HCU Network Australia. You can read the media release here.